-
Study aim
-
Comparison of the closure rate of a patent ductus arteriosus between oral and intravenous paracetamol in hemodynamically stable preterm infants
-
Design
-
This is a Phase 3, randomized, triple-blind, parallel-group, controlled clinical trial involving 98 premature infants, in which the randomization process is performed using the random function in Microsoft Excel.
-
Settings and conduct
-
In the NICU at Shohadaye Tajrish Teaching Hospital, echocardiography will be performed prior to the initiation of acetaminophen, as well as three and five days after the start of the medication. The infants' parents are unaware of the specific drug formulation used. Blinding is maintained for the principal investigator, healthcare staff (including other physicians and nurses), the outcome assessor, the data analyst, and the Data Safety and Monitoring Committee.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Preterm infants up to 3 days of age with stable hemodynamics, a clinically significant patent ductus arteriosus, and written informed consent for participation in the study.
Exclusion criteria: Term infants, infants older than 3 days, unstable hemodynamic status, and lack of consent from the parents or the infant's legal guardian.
-
Intervention groups
-
Ninety-eight preterm infants with clinically significant PDA will be enrolled in the study. Using a block randomization method, they will be equally assigned to two groups: the first group will receive paracetamol orally, while the second group will receive it intravenously. The dosage, administration intervals, and duration of treatment in both groups will follow the established treatment protocol, and the targeted outcomes will be evaluated and compared between the two groups.
-
Main outcome variables
-
Demographic data, hemodynamic assessment indices (echocardiography), type of acetaminophen formulation and duration of use, and laboratory tests.